NCT07533019

A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

A Phase 2, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Non-Segmental Vitiligo

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 48 weeks, including screening.

Conditions

• Vitiligo
• Non-Segmental Vitiligo (NSV)

Interventions

Type	Name	Description
DRUG	LY4005130	Administered IV
DRUG	Placebo	Administered IV

Timeline

• Start date: 2026-04-14
• Primary completion: 2027-05-21
• Completion: 2027-09-10
• First posted: 2026-04-16
• Last updated: 2026-04-16

Locations

35 sites across 5 countries: United States, Belgium, Canada, China, Poland

Regulatory

• FDA-regulated drug study